Roche and Gilead Sciences launched a Phase III clinical trial in severe COVID-19 pneumonia, testing Roche’s Actemra/RoActemra with Gilead’s remdesivir.

A top U.S. scientist said governments should not count on a successful vaccine against COVID-19 being developed anytime soon when deciding whether to ease restrictions imposed to curb the pandemic.

Biogen filed a lawsuit against a New York life sciences company over alleged patent infringements related to the experimental Alzheimer’s disease treatment aducanumab.

Following close on the heels of the company’s vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.

The European Commission approved Pfizer Inc.’s Ruxience (rituximab) – a monoclonal antibody and biosimilar to MabThera – for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

Regeneron and Sanofi dosed the first patient outside of the United States with the rheumatoid arthritis drug Kevzara as part of a second global clinical trial assessing the medication as a treatment for COVID-19, the disease caused by the novel coronavirus pandemic.

Sanofi and Regeneron Pharmaceuticals expanded a clinical trial of the companies’ rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.

San Francisco-based Vir Biotechnology indicated the company identified several human monoclonal antibody (mAb) candidates against SARS-CoV-2, the virus causing COVID-19.

Gilead Sciences Inc. is buying Forty Seven Inc. for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards.

Regeneron Pharmaceuticals Inc. is ramping up efforts to develop a set of coronavirus treatments, which could be available for testing or use in some patients within a few months, the drugmaker said on Thursday.